E Bissio1, M G Barbás2, M B Bouzas3, A Cudolá2, H Salomón4, L Espínola5, S Fernández Giuliano3, S Kademián2, L Mammana3, M L Suárez Ornani4, G Ravasi6, M Vila7, I Zapiola3, C Falistocco5. 1. Fundación Centro de Estudios Infectológicos (FUNCEI), Ciudad de Buenos Aires, Argentina ebissio@gmail.com. 2. Laboratorio Central de Córdoba, Ciudad de Córdoba, Argentina. 3. Hospital Muñiz, Ciudad de Buenos Aires, Argentina. 4. Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina. 5. Dirección de Sida, Ministerio de Salud de la Nación, Ciudad de Buenos Aires, Argentina. 6. Pan American Health Organization, Washington, DC, USA. 7. Pan American Health Organization, Ciudad de Buenos Aires, Argentina.
Abstract
BACKGROUND: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. OBJECTIVES: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHO-proposed methodology. METHODS: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. RESULTS: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean ± SD age was 35 ± 11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2% PI-RAMs) and 13% (±4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. CONCLUSIONS: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina's Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
BACKGROUND: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. OBJECTIVES: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHO-proposed methodology. METHODS: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. RESULTS: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean ± SD age was 35 ± 11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2% PI-RAMs) and 13% (±4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. CONCLUSIONS: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina's Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
Authors: Marc Noguera-Julian; Dianna Edgil; P Richard Harrigan; Paul Sandstrom; Catherine Godfrey; Roger Paredes Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226
Authors: Monica B Arruda; Lídia T Boullosa; Cynthia C Cardoso; Carolina M da Costa; Carlos Rb Alves; Shirlene Ts de Lima; Helena T Kaminski; Agdemir W Aleixo; Ana Op Esposito; Ana Ms Cavalcanti; Maristela Riedel; José C Couto-Fernandez; Selma B Ferreira; Ivi Cm de Oliveira; Loreci E Portal; Hilda Hc Wolf; Sandra B Fernandes; Maria I de M C Pardini; Manoel Vc Feiteiro; Fernanda M Tolentino; Ricardo S Diaz; Giselle Isl Lopes; Roberta Bl Francisco; Nazle Mc Véras; Ana F Pires; Miriam Franchini; Fábio Mesquita; Amilcar Tanuri Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396
Authors: Kevin Melody; Chandra N Roy; Christopher Kline; Mackenzie L Cottrell; Dwayne Evans; Kathleen Shutt; Pleuni S Pennings; Brandon F Keele; Moses Bility; Angela D M Kashuba; Zandrea Ambrose Journal: J Virol Date: 2020-03-31 Impact factor: 6.549